Patents Issued For Inotek Pharmaceuticals’ Lead Clinical Compounds In Glaucoma And Contrast-Induced Nephropathy
Nov 21st 2008Drug InformationEye Health
Inotek Pharmaceuticals Corporation announced today that the United States Patent and Trademark Office has issued two new patents covering the Company’s two lead clinical compounds. US Patent number 7,423,144 relates to INO-8875, in clinical development as a novel treatment for glaucoma and US Patent number 7,432,369 relates to INO-4885, in clinical development for the prevention of contrast-induced nephropathy.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
